UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000005979 |
|---|---|
| Receipt number | R000007073 |
| Scientific Title | Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer |
| Date of disclosure of the study information | 2011/07/15 |
| Last modified on | 2011/07/15 15:50:46 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer
Acronym
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer
Scientific Title
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer
Scientific Title:Acronym
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer
Region
| Japan |
Condition
Condition
Breast cancer
Classification by specialty
| Breast surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate the efficacy and safety of weekly Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for breast cancer
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Pathological complete response rate
Key secondary outcomes
Response rate
Breast conserving rate
Adverse event
Rate of patients with residual peripheral neuropathy
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Nab-paclitaxel followed by FEC
Nab-paclitaxel 100 mg/m2 i.v. weekly for 12 weeks followed by FEC (5-FU 500mg/m2 i.v.; Epirubicin 100 mg/m2 i.v. [or if given with Trastuzumab 75 mg/m2 i.v.]; Cyclophosphamide 500 mg/m2 i.v.) on Day 1 every 21 days for 4 cycles
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Female
Key inclusion criteria
1) Histologically confirmed primary breast cancer
2) Clinical stage I-IIIB
3) Patients who scheduled for surgery after neoadjuvant chemotherapy
4) With estimative lesion
5) Age >= 20 years
6) No prior surgery, radiation, chemotherapy and endocrine therapy
7) ECOG performance status of 0 or 1
8) Required baseline laboratory parameters (within 14 days before registration)
WBC >= 4,000/mm3
Neu >= 2,000/mm3
Plt >= 10.0x104/mm3
Hb >= 9.0g/dL
AST <= 100 IU/L
ALT <= 100 IU/L
T-Bil <= 1.5mg/dL
Cre <= 1.5mg/dL
9) Written informed consent
Key exclusion criteria
1) Allergy of the medication
2) Synchronous or metachronous (within 5 years) double cancers
3) Serious complication
4) Contraindication to the study drugs
5) Peripheral neuropathy
6) Pregnancy, breast feeding or wish of future bearing
7) Patients considered inappropriate by the study investigator
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Shoji Oura |
Organization
Wakayama Medical University
Division name
Department of Thoracic and Cardiovascular Surgery
Zip code
Address
811-1, Kimiidera, Wakayama City, Wakayama 641-8509, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Wakayama Medical University
Division name
Department of Thoracic and Cardiovascular Surgery
Zip code
Address
811-1, Kimiidera, Wakayama City, Wakayama 641-8509, Japan
TEL
073-441-0615
Homepage URL
Sponsor or person
Institute
Wakayama Medical University
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Minami Wakayama Medical Center
Hashimoto Municipal Hospital
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 07 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2011 | Year | 06 | Month | 17 | Day |
Date of IRB
Anticipated trial start date
| 2011 | Year | 07 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 06 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2011 | Year | 07 | Month | 15 | Day |
Last modified on
| 2011 | Year | 07 | Month | 15 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007073
